{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T00:23:09Z","timestamp":1719706989492},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,29]]},"DOI":"10.7759\/cureus.63445","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T10:45:17Z","timestamp":1719657917000},"source":"Crossref","is-referenced-by-count":0,"title":["Anthocyanins as Adjuvant Treatment for Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Naveed N","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaf J","family":"Zurayyir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam  Y","family":"Almuslem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riyadh","family":"Alshamrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razan A","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghalia Hasan  T","family":"Sulaimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamdouh Hussein T","family":"Sulimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam Salah  F","family":"Albalawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawan M","family":"Alzehair Alqahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman M","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda  H","family":"Aljawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawad A","family":"Alsuliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr RM","year":"2016","unstructured":"Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin North Am. 2016, 45:639-52. 10.1016\/j.gtc.2016.07.003","journal-title":"Gastroenterol Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella ME","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015, 313:2263-73. 10.1001\/jama.2015.5370","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong RJ","year":"2015","unstructured":"Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015, 148:547-55. 10.1053\/j.gastro.2014.11.039","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam M","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020, 158:1999-2014.e1. 10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0316-6","article-title":"From NAFLD to MAFLD: when pathophysiology succeeds","volume":"17","author":"Tilg H","year":"2020","unstructured":"Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020, 17:387-8. 10.1038\/s41575-020-0316-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell PB","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, et al.. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022, 42:e168-85. 10.1161\/ATV.0000000000000153","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.584396","article-title":"Distinct cause of death profiles of hospitalized non-alcoholic fatty liver disease: a 10 years' cross-sectional multicenter study in China","volume":"7","author":"Lin Y","year":"2020","unstructured":"Lin Y, Gong X, Li X, et al.. Distinct cause of death profiles of hospitalized non-alcoholic fatty liver disease: a 10 years' cross-sectional multicenter study in China. Front Med (Lausanne). 2020, 7:584396. 10.3389\/fmed.2020.584396","journal-title":"Front Med (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence KK","year":"2021","unstructured":"Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab. 2021, 50:101143. 10.1016\/j.molmet.2020.101143","journal-title":"Mol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001191","article-title":"Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?","volume":"30","author":"Oikonomou D","year":"2018","unstructured":"Oikonomou D, Georgiopoulos G, Katsi V, et al.. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?. Eur J Gastroenterol Hepatol. 2018, 30:979-85. 10.1097\/MEG.0000000000001191","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S62831","article-title":"Molecular pathways in non-alcoholic fatty liver disease","volume":"7","author":"Berlanga A","year":"2014","unstructured":"Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014, 7:221-39. 10.2147\/CEG.S62831","journal-title":"Clin Exp Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2019.07.063","article-title":"A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach","volume":"13","author":"Sangouni AA","year":"2019","unstructured":"Sangouni AA, Ghavamzadeh S. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. Diabetes Metab Syndr. 2019, 13:2917-22. 10.1016\/j.dsx.2019.07.063","journal-title":"Diabetes Metab Syndr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14709","article-title":"Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management","volume":"50","author":"Huang TD","year":"2020","unstructured":"Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J. 2020, 50:1038-47. 10.1111\/imj.14709","journal-title":"Intern Med J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16638830","article-title":"Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials","volume":"9","author":"Zelber-Sagi S","year":"2016","unstructured":"Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol. 2016, 9:392-407. 10.1177\/1756283X16638830","journal-title":"Therap Adv Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2018.78118","article-title":"Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)","volume":"4","author":"Tomasiewicz K","year":"2018","unstructured":"Tomasiewicz K, Flisiak R, Halota W, et al.. Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clin Exp Hepatol. 2018, 4:153-7. 10.5114\/ceh.2018.78118","journal-title":"Clin Exp Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"9","year":"2016","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016, 9.65-90. 10.1159\/000443344","journal-title":"Obes Facts"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000758","article-title":"A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease","volume":"94","author":"Zhang PW","year":"2015","unstructured":"Zhang PW, Chen FX, Li D, Ling WH, Guo HH. A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease. Medicine (Baltimore). 2015, 94:e758. 10.1097\/MD.0000000000000758","journal-title":"Medicine (Baltimore)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7199","article-title":"The effect of (Cornus mas L.) fruit extract on liver function among patients with nonalcoholic fatty liver: a double-blind randomized clinical trial","volume":"35","author":"Sangsefidi ZS","year":"2021","unstructured":"Sangsefidi ZS, Yarhosseini F, Hosseinzadeh M, Ranjbar A, Akhondi-Meybodi M, Fallahzadeh H, Mozaffari-Khosravi H. The effect of (Cornus mas L.) fruit extract on liver function among patients with nonalcoholic fatty liver: a double-blind randomized clinical trial. Phytother Res. 2021, 35:5259-68. 10.1002\/ptr.7199","journal-title":"Phytother Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon-132309","article-title":"Effectiveness of grape seed extract in patients with nonalcoholic fatty liver: a randomized double-blind clinical study","volume":"22","author":"Mojiri-Forushani H","year":"2022","unstructured":"Mojiri-Forushani H, Hemmati A, Khanzadeh A. Effectiveness of grape seed extract in patients with nonalcoholic fatty liver: a randomized double-blind clinical study. Hepat Mon. 2022, 22:132309. 10.5812\/hepatmon-132309","journal-title":"Hepat Mon"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2023.04.018","article-title":"Effect of Cornus mas L. fruit extract on blood pressure, anthropometric and body composition indices in patients with non-alcoholic fatty liver disease: a double-blind randomized controlled trial","volume":"56","author":"Yarhosseini F","year":"2023","unstructured":"Yarhosseini F, Sangouni AA, Sangsefidi ZS, et al.. Effect of Cornus mas L. fruit extract on blood pressure, anthropometric and body composition indices in patients with non-alcoholic fatty liver disease: a double-blind randomized controlled trial. Clin Nutr ESPEN. 2023, 56:18-24. 10.1016\/j.clnesp.2023.04.018","journal-title":"Clin Nutr ESPEN"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117068","article-title":"Effects of Cornus mas L. on anthropometric and biochemical parameters among metabolic associated fatty liver disease patients: randomized clinical trial","volume":"318","author":"Bayram HM","year":"2024","unstructured":"Bayram HM, Iliaz R, Gunes FE. Effects of Cornus mas L. on anthropometric and biochemical parameters among metabolic associated fatty liver disease patients: randomized clinical trial. J Ethnopharmacol. 2024, 318:117068. 10.1016\/j.jep.2023.117068","journal-title":"J Ethnopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2022.102843","article-title":"Curcumin as adjuvant treatment in patients with non-alcoholic fatty liver (NAFLD) disease: a systematic review and meta-analysis","volume":"68","author":"Ngu MH","year":"2022","unstructured":"Ngu MH, Norhayati MN, Rosnani Z, Zulkifli MM. Curcumin as adjuvant treatment in patients with non-alcoholic fatty liver (NAFLD) disease: a systematic review and meta-analysis. Complement Ther Med. 2022, 68:102843. 10.1016\/j.ctim.2022.102843","journal-title":"Complement Ther Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/biom12060852","article-title":"The benefits of anthocyanins against obesity-induced inflammation","volume":"12","author":"Ngamsamer C","year":"2022","unstructured":"Ngamsamer C, Sirivarasai J, Sutjarit N. The benefits of anthocyanins against obesity-induced inflammation. Biomolecules. 2022, 12:852. 10.3390\/biom12060852","journal-title":"Biomolecules"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009, 6:e1000100. 10.1371\/journal.pmed.1000100","journal-title":"PLoS Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref26","unstructured":"The R Project for Statistical Computing. (2021). https.\/\/www.R-project.org."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi S","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019, 22:153-60. 10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"ref28","unstructured":"dmetar. doing meta-analysis in R. https:\/\/dmetar.protectlab.org\/."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/qhc.12.4.298","article-title":"Systematic reviews of the effectiveness of quality improvement strategies and programmes","volume":"12","author":"Grimshaw J","year":"2003","unstructured":"Grimshaw J, McAuley LM, Bero LA, et al.. Systematic reviews of the effectiveness of quality improvement strategies and programmes. Qual Saf Health Care. 2003, 12:298-303. 10.1136\/qhc.12.4.298","journal-title":"Qual Saf Health Care"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1023\/a:1005661516165","article-title":"Fatty infiltration of liver in hyperlipidemic patients","volume":"45","author":"Assy N","year":"2000","unstructured":"Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000, 45:1929-34. 10.1023\/a:1005661516165","journal-title":"Dig Dis Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1039\/c3fo60495k","article-title":"Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans","volume":"5","author":"Chang HC","year":"2014","unstructured":"Chang HC, Peng CH, Yeh DM, Kao ES, Wang CJ. Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans. Food Funct. 2014, 5:734-9. 10.1039\/c3fo60495k","journal-title":"Food Funct"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101843","article-title":"Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: a case-control and an intervention study","volume":"46","author":"Zhu X","year":"2022","unstructured":"Zhu X, Lin X, Zhang P, Liu Y, Ling W, Guo H. Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: a case-control and an intervention study. Clin Res Hepatol Gastroenterol. 2022, 46:101843. 10.1016\/j.clinre.2021.101843","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2019.05.005","article-title":"Antiobesity effects of anthocyanins on mitochondrial biogenesis, inflammation, and oxidative stress: a systematic review","volume":"66","author":"Gomes JV","year":"2019","unstructured":"Gomes JV, Rigolon TC, Souza MS, Alvarez-Leite JI, Lucia CM, Martino HS, Rosa CO. Antiobesity effects of anthocyanins on mitochondrial biogenesis, inflammation, and oxidative stress: a systematic review. Nutrition. 2019, 66:192-202. 10.1016\/j.nut.2019.05.005","journal-title":"Nutrition"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-023-08666-0","article-title":"Biomarkers of liver diseases","volume":"50","author":"Tamber SS","year":"2023","unstructured":"Tamber SS, Bansal P, Sharma S, Singh RB, Sharma R. Biomarkers of liver diseases. Mol Biol Rep. 2023, 50:7815-23. 10.1007\/s11033-023-08666-0","journal-title":"Mol Biol Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/740954","article-title":"Evaluation of the effects of Cornus mas L. fruit extract on glycemic control and insulin level in type 2 diabetic adult patients: a randomized double-blind placebo-controlled clinical trial","volume":"2015","author":"Soltani R","year":"2015","unstructured":"Soltani R, Gorji A, Asgary S, Sarrafzadegan N, Siavash M. Evaluation of the effects of Cornus mas L. fruit extract on glycemic control and insulin level in type 2 diabetic adult patients: a randomized double-blind placebo-controlled clinical trial. Evid Based Complement Alternat Med. 2015, 2015:740954. 10.1155\/2015\/740954","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat K","year":"2010","unstructured":"Promrat K, Kleiner DE, Niemeier HM, et al.. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010, 51:121-9. 10.1002\/hep.23276","journal-title":"Hepatology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02588.x","article-title":"Effect of cranberry extracts on lipid profiles in subjects with type 2 diabetes","volume":"25","author":"Lee IT","year":"2008","unstructured":"Lee IT, Chan YC, Lin CW, Lee WJ, Sheu WH. Effect of cranberry extracts on lipid profiles in subjects with type 2 diabetes. Diabet Med. 2008, 25:1473-7. 10.1111\/j.1464-5491.2008.02588.x","journal-title":"Diabet Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6476","article-title":"The effect of Cornus mas fruit extract consumption on lipid profile, glycemic indices, and leptin in postmenopausal women - a randomized clinical trial","volume":"33","author":"Gholamrezayi A","year":"2019","unstructured":"Gholamrezayi A, Aryaeian N, Rimaz S, Abolghasemi J, Fallah S, Moradi N, Taghizadeh M. The effect of Cornus mas fruit extract consumption on lipid profile, glycemic indices, and leptin in postmenopausal women - a randomized clinical trial. Phytother Res. 2019, 33:2979-88. 10.1002\/ptr.6476","journal-title":"Phytother Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3945\/jn.110.124701","article-title":"Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome","volume":"140","author":"Basu A","year":"2010","unstructured":"Basu A, Du M, Leyva MJ, et al.. Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome. J Nutr. 2010, 140:1582-7. 10.3945\/jn.110.124701","journal-title":"J Nutr"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/nu13062121","article-title":"Effects of anthocyanin supplementation on reduction of obesity criteria: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Park S","year":"2021","unstructured":"Park S, Choi M, Lee M. Effects of anthocyanin supplementation on reduction of obesity criteria: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2021, 13:2121. 10.3390\/nu13062121","journal-title":"Nutrients"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2740364","article-title":"Antiobesity effects of anthocyanins in preclinical and clinical studies","volume":"2017","author":"Azzini E","year":"2017","unstructured":"Azzini E, Giacometti J, Russo GL. Antiobesity effects of anthocyanins in preclinical and clinical studies. Oxid Med Cell Longev. 2017, 2017:2740364. 10.1155\/2017\/2740364","journal-title":"Oxid Med Cell Longev"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutres.2023.04.004","article-title":"Anthocyanins ameliorate obesity-associated metainflammation: preclinical and clinical evidence","volume":"114","author":"Santamarina AB","year":"2023","unstructured":"Santamarina AB, Calder PC, Estadella D, Pisani LP. Anthocyanins ameliorate obesity-associated metainflammation: preclinical and clinical evidence. Nutr Res. 2023, 114:50-70. 10.1016\/j.nutres.2023.04.004","journal-title":"Nutr Res"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-013-0693-5","article-title":"Investigation of the lipid-modifying and antiinflammatory effects of Cornus mas L. supplementation on dyslipidemic children and adolescents","volume":"34","author":"Asgary S","year":"2013","unstructured":"Asgary S, Kelishadi R, Rafieian-Kopaei M, Najafi S, Najafi M, Sahebkar A. Investigation of the lipid-modifying and antiinflammatory effects of Cornus mas L. supplementation on dyslipidemic children and adolescents. Pediatr Cardiol. 2013, 34:1729-35. 10.1007\/s00246-013-0693-5","journal-title":"Pediatr Cardiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162089","article-title":"Effects of anthocyanin on serum lipids in dyslipidemia patients: a systematic review and meta-analysis","volume":"11","author":"Liu C","year":"2016","unstructured":"Liu C, Sun J, Lu Y, Bo Y. Effects of anthocyanin on serum lipids in dyslipidemia patients: a systematic review and meta-analysis. PLoS ONE. 2016, 11:e0162089. 10.1371\/journal.pone.0162089","journal-title":"PLoS ONE"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-012-0393-6","article-title":"Blueberry anthocyanins at doses of 0.5 and 1 % lowered plasma cholesterol by increasing fecal excretion of acidic and neutral sterols in hamsters fed a cholesterol-enriched diet","volume":"52","author":"Liang Y","year":"2013","unstructured":"Liang Y, Chen J, Zuo Y, Ma KY, Jiang Y, Huang Y, Chen ZY. Blueberry anthocyanins at doses of 0.5 and 1 % lowered plasma cholesterol by increasing fecal excretion of acidic and neutral sterols in hamsters fed a cholesterol-enriched diet. Eur J Nutr. 2013, 52:869-75. 10.1007\/s00394-012-0393-6","journal-title":"Eur J Nutr"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3945\/jn.114.205674","article-title":"Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients","volume":"145","author":"Li D","year":"2015","unstructured":"Li D, Zhang Y, Liu Y, Sun R, Xia M. Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients. J Nutr. 2015, 145:742-8. 10.3945\/jn.114.205674","journal-title":"J Nutr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/259380-anthocyanins-as-adjuvant-treatment-for-non-alcoholic-fatty-liver-disease-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T10:45:24Z","timestamp":1719657924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/259380-anthocyanins-as-adjuvant-treatment-for-non-alcoholic-fatty-liver-disease-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.63445","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,29]]}}}